Loss of immunological self-tolerance followed by attack of self-reactive T cells to target organs plays a major role in the formation of autoimmune diseases such as multiple sclerosis (MS). In a very recent study published in Science, our researchers (in collaboration with Johannes Gutenberg University Medical Center and BioNTech) employed a non-inflammatory RNA vaccine that
EU Comission grants conditional marketing authorization for SARS-CoV-2 vaccine
For further information, please refer to the original press release.
U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use
For further information, please refer to the original press release.
Biotech: a Booming Industry – 3sat Makro
We build the foundation for personalized therapies! Join Eva Schmidt on her tour through TRON for the latest 3sat Makro show about the biotech industry in Germany and our participation as a translational research institute!
PhD Student Isabell Keil wins poster prize at CLINAM 2020
TRON is thrilled that PhD candidate Isabell Keil has won a prize for her poster at CLINAM 12/2020 (European Foundation for Clinical Nanomedicine’s 12th Annual Meeting)! Isa’s work, featured in the conference’s Basic Nanomedicine category, is to develop nanoparticle‐based mRNA carrier systems for transient immunomodulation of immune cells. Isa’s poster, along with all poster presentations,
International initiative TESLA identifies parameters for cancer vaccine or cell therapy advancement
Published in Cell: TRON is part of a 36-member alliance led by the Parker Institute and Cancer Research Institute identifying parameters for better vaccine design in the fight against cancer. As part of TESLA (Tumor Neoantigen Selection Alliance), TRON performed advanced computational analysis on samples from melanoma and non-small cell lung cancer to identify characteristics
Multi-omics characterization of the 4T1 murine mammary gland tumor model
The murine mammary carcinoma cell line 4T1 is a widely used syngeneic tumor model for human breast cancer and specifically triple-negative breast cancer (TNBC). Profiling tumor models is important to translate pre-clinical findings appropriately. The authors aimed to complement the evaluation of 4T1 as adequate breast cancer or even TNBC model. Analysis of the whole-exome
A liposomal RNA vaccine augments the antitumor activity of local radiotherapy in mice
TRON is delighted to announce the publication of a scientific article in OncoImmunology.
TRON wears white for A Future #Immune2Cancer
TRON is proud to join the Cancer Research Institute this June 12 in bringing global awareness about the life-saving potential of cancer immunotherapy. By wearing white together, we are driving the future of immune-based science and medicine for cancer treatments, and ultimately, cures. Learn more about TRON’s mission and work at www.tron-mainz.de.
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation
TRON is delighted to announce a scientific article published in Oncotarget.
TRON’s activities against the Coronavirus pandemic
As an innovative immunological research institute, TRON was asked by a renowned industrial partner to support the development of a vaccine against the currently pandemic coronavirus with preclinical studies.
Dr. Luisa Bresadola awarded BMS Young Scientist prize
We are delighted to announce that TRON scientist Dr. Luisa Bresadola has won the Bristol-Myers-Squibb Young Scientist award in the field of immune-oncology! Luisa’s work comprises analysis of head and neck squamous cell carcinoma next-generation sequencing data, generated by TRON in collaboration with the University of Birmingham, to determine tumor evoluation in this cancer entity.
